NAFLD Clinical Trials

65 recruitingLast updated: June 18, 2026

There are 65 actively recruiting nafld clinical trials across 24 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3. Top locations include Paris, France, Angers, France, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


NAFLD Trials at a Glance

65 actively recruiting trials for nafld are listed on ClinicalTrialsFinder across 6 cities in 24 countries. The largest study group is Not Applicable with 30 trials, with the heaviest enrollment activity in Paris, Angers, and Beijing. Lead sponsors running nafld studies include Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, and Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Browse nafld trials by phase

Treatments under study

About NAFLD Clinical Trials

Looking for clinical trials for NAFLD? There are currently 45 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new NAFLD trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about NAFLD clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 65 trials

Recruiting
Not Applicable

Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients

Liver FibrosisNon-alcoholic Fatty Liver Disease NAFLDAlcoholic Liver Disease (ALD)
University Hospital, Angers1,788 enrolled13 locationsNCT05699018
Recruiting
Phase 2

Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

NAFLD
University of Virginia50 enrolled1 locationNCT05424003
Recruiting

A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes

NAFLD - Non-Alcoholic Fatty Liver DiseaseNAFLD and NASHNAFLD Cirrhosis
The Affiliated Hospital of Hangzhou Normal University20,000 enrolled1 locationNCT07241195
Recruiting
Phase 1

Bicalutamide Therapy in Young Women With NAFLD and PCOS

PCOSNAFLD
University of California, San Francisco50 enrolled1 locationNCT05979389
Recruiting
Phase 2

Digoxin In NASH (CODIN)

MASLDMASH - Metabolic Dysfunction-Associated SteatohepatitisFatty Liver Disease+5 more
Yale University144 enrolled2 locationsNCT06588699
Recruiting
Phase 1

Evaluating the Pharmacokinetics and Safety of Miricorilant

Nonalcoholic Steatohepatitis (NASH)Non-alcoholic Fatty Liver Disease NAFLDMetabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis+1 more
Corcept Therapeutics15 enrolled1 locationNCT07553663
Recruiting
Not Applicable

Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis

Liver Metastasis Colon CancerLiver SteatosesNAFLD
Anton Skaro124 enrolled1 locationNCT05884723
Recruiting
Not Applicable

Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals

NAFLD
Steno Diabetes Center Copenhagen8 enrolled2 locationsNCT05842850
Recruiting

Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease

Liver NeoplasmLiver FibrosisHBV Infection+1 more
Nanfang Hospital, Southern Medical University240 enrolled1 locationNCT07265544
Recruiting

Androgens and NAFLD Longitudinal Cohort Study

PCOSNAFLDNASH
University of California, San Francisco150 enrolled2 locationsNCT06124261
Recruiting

Accurate Point of Care Liver Disease Diagnostics (Phase 2)

MASLDNAFLD (Nonalcoholic Fatty Liver Disease)NAFLD+1 more
University of California, San Diego26 enrolled1 locationNCT07518784
Recruiting
Not Applicable

Effects of Two Different Exercise Programs and Diet in Obese Subjects With NAFLD

ObesityNAFLD
Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis90 enrolled1 locationNCT06186869
Recruiting
Not Applicable

Target of Suv420h1/2 in Hepatocytes

NAFLD
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico260 enrolled1 locationNCT06332677
Recruiting
Phase 1

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

Nonalcoholic Steatohepatitis (NASH)Metabolic dysfunction-associated steatohepatitis (MASH)Non-alcoholic Fatty Liver Disease NAFLD+1 more
Corcept Therapeutics8 enrolled1 locationNCT06947304
Recruiting
Phase 2

Milk Thistle Clinical Trial in Pediatric NAFLD

Non-alcoholic Fatty Liver Disease NAFLD
University Hospitals Cleveland Medical Center20 enrolled1 locationNCT06477146
Recruiting
Phase 2

A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH )

NAFLD - Non-Alcoholic Fatty Liver Disease
Hinova Pharmaceuticals Inc.80 enrolled2 locationsNCT07308548
Recruiting
Not Applicable

Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis

NAFLD - Non-Alcoholic Fatty Liver DiseaseMASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
ContextVision AB110 enrolled1 locationNCT07270601
Recruiting
Not Applicable

Comparison of Two sTRAtegies For the Non-Invasive Diagnosis of advanCed Liver Fibrosis in NAFLD

NAFLD
University Hospital, Angers1,045 enrolled20 locationsNCT04681573
Recruiting
Not Applicable

Human Liver ORganoids as a Model to Study the Development of Non-Alcoholic SteatOhepatitis (NASH)

NAFLD
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico60 enrolled1 locationNCT06856252
Recruiting
Not Applicable

The Liver BIoBank Lombardia of Fatty Liver

Cardiovascular DiseasesNAFLDPrecision Medicine
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico2,500 enrolled1 locationNCT06566105